Leukocytosis may develop in women undergoing ovulation induction. The production of blood leukocytes and their numbers in circulation are regulated by complex interactions involving endogenous haematopoietic cytokines, such as granulocyte-colony stimulating factor (G-CSF), monocyte-colony stimulating factor (M-CSF), and interleukins. The purpose of this prospective study was to explore the presence of leukocytosis in women who receive urinary menotrophins, and to determine whether haematopoietic cytokines are changed in the stimulation process. Controls were volunteers of the same age range, not taking any medication, who received daily saline injections. Subjects underwent phlebotomy at defined points for determination of complete blood counts, G-CSF, M-CSF, and interleukin-6 concentrations. Baseline white blood cell (WBC) counts were similar in patients and controls. In menotrophin-treated patients the WBC counts rose significantly (4.19 ⍨ 0.28 to 6.37 ⍨ 0.71) during the stimulation and peaked in the luteal phase (P ⍧ 0.037). In contrast, WBC counts decreased in controls. Other leukocytic lineages were not affected. In treated patients G-CSF concentrations rose significantly (P ⍧ 0.028 versus controls), while changes in M-CSF and interleukin-6 were not significant.
Introduction
The production of blood leukocytes and their numbers in circulation are regulated by complex interactions involving endogenous haematopoietic cytokines, such as granulocytecolony stimulating factor (G-CSF) and monocyte-colony stimulating factor (M-CSF), and several of the interleukins (Quesenberry, 1995) . G-CSF and M-CSF are measurable in circulation, and their concentrations appear to be regulated in response to immunological or physiological challenges such as infection and pregnancy. Recently, we presented evidence that patients undergoing ovarian stimulation with exogenous gonadotrophins experience a significant increase in their white blood cell (WBC) count towards the end of the follicular phase (Kemmann and Fisch, 1995) . This observation was made in a retrospective fashion and seen in a cohort of women who were also exposed to other medication. To examine whether gonadotrophin stimulation results in leukocytosis, we initiated a controlled, prospective study in women who only received exogenous gonadotrophins for ovarian stimulation. We wished not only to study whether leukocytosis would occur in response to menotrophin stimulation, but also to see if certain endogenous haematopoietins, specifically G-CSF and M-CSF, increase in response to the exogenous gonadotrophic stimulation of the ovaries.
Materials and methods
The study and the associated informed consent form were approved by the Institutional Review Board of UMDNJ-Robert Wood Johnson Medical School. Ten patients who were undergoing ovarian stimulation as part of their infertility treatment were enrolled in the study. These patients were in good general health and did not receive any medication other than that required for ovarian stimulation. All patients had been trying to conceive for more than one year, were in the age range 27-37 years, and had documented tubal patency. The diagnosis included ovulation dysfunction, male factor infertility, and unexplained infertility. Past therapy with clomiphene citrate and intrauterine insemination had not been successful.
Patients were treated with daily i.m. injection of urinary menotrophins (Metrodin ® , Serono Inc., Randolph, MA, USA) at a typical dose of 150 units/day i.m. beginning on cycle day 3. Patients were evaluated every 2-3 days between 0730 and 0900 h for determination of serum oestradiol concentrations. Once oestradiol concentrations exceeded 400 pg/ml, transvaginal sonographic ovarian follicle measurements were obtained. Monitoring was used to adjust the dose and duration of menotrophin injections and determine the time of administration of human chorionic gonadotrophins (HCG) at the end of the stimulation phase. A minimum dose of 1200 units menotrophins was given per patient per cycle. HCG (10 000 IU; Profasi, Serono Inc.) were given when oestradiol Ͼ400 pg/ml and one or more follicles Ͼ18 mm in diameter. Intrauterine insemination was scheduled for 36 h later. All patients were seen one week after HCG administration for the possible development of ovarian hyperstimulation syndrome (OHSS). Patients did not receive any gonadotrophin releasing hormone agonist. Seven healthy women who had regular predictable cycles of 28 Ϯ 2 days were used as controls. These women were within the same age range as the patients and not taking any hormonal or other medication. These controls underwent daily sham injections of 2 ml saline from cycle day 3-10.
Complete blood counts with differential and platelet counts (CBC/ diff) were performed in menotrophin-treated patients at the early follicular phase (EF) on cycle day 3 prior to beginning treatment; the mid-follicular phase (MF), 4-6 days after treatment; the late follicular phase (LF), within 40 h prior to HCG administration; and the mid- Table I . White blood cell (WBC) counts and mean serum concentrations (Ϯ SEM) of granulocyte-colony stimulating factor (G-CSF) and monocyte-colony stimulating factor (M-CSF) in treated patients (P) and untreated controls (C) in relation to cycle phase (EF: early follicular, MF: mid-follicular, LF: late follicular, ML: mid-luteal phase) luteal phase (ML), one week after HCG administration. In control subjects, CBC/diff was measured at EF (cycle day 3) and LF (cycle day 10). In addition, blood for the determination of haematopoietic cytokines G-CSF, M-CSF, and IL-6 were drawn at the same time points as the CBC/diff in subjects and controls. CBC/diff measurements were performed by a licensed commercial provider (Metpath, Teterboro Laboratories, Teterboro, NJ, USA). Serum oestradiol measurements were performed by radioimmunoassay as described (Ransom et al., 1994) . For cytokine determinations, sera were separated and clarified by high speed centrifugation and stored at -70°C until assayed. Estimation of serum concentrations of G-CSF, M-CSF, and interleukin-6 (IL-6) were performed by enzymelinked immunosorbent (ELISA) assays using the respective Quantikine ® kits (R&D Systems, Minneapolis, MN, USA).
Descriptive statistics are shown as mean Ϯ SEM unless otherwise specified. In order to extract the effects of menotrophin stimulation from random intra-or inter-individual variation and possible effects of endogenous menstrual endocrine factors on haematopoiesis and cytokine concentrations, the absolute or relative individual changes in study parameters from EF to LF were compared between control subjects and treated patients. Significance was determined at the concentration of P Ͻ 0.05.
Results
Serum oestradiol concentrations increased in all menotrophintreated patients, rising from 54 Ϯ 9 pg/ml at EF to 930 Ϯ 118 pg/ml at LF (P Ͻ 0.0001, paired t-test). All treated patients received HCG and had elevated progesterone concentrations in the mid-luteal phase, consistent with an ovulatory response. None of the patients had signs of OHSS.
In menotrophin-treated patients, WBC counts rose progressively during the follicular phase and peaked in the luteal phase (Table I) . Baseline (EF) mean WBC was not significantly different between patients and controls. The mean of the treated group increased significantly at LF (6.7-8.6 ϫ10 3 per mm 3 , an increase of 1.9 Ϯ 0.53ϫ10 3 per mm 3 ; P Ͻ 0.05 versus corresponding control, t-test). Mean WBC of controls decreased from 6.4 to 5.9ϫ10 3 per mm 3 at LF (decrease of 0.4 Ϯ 0.92ϫ10 3 per mm 3 , no significant change). The mean absolute neutrophil count of the treated group increased from 4.19 Ϯ 0.28ϫ10 3 per mm 3 at EF to 6.37 Ϯ 0.71 ϫ10 3 per mm 3 at LF (increase of over 50% with 2.19 Ϯ 0.54ϫ10 3 per mm 3 ; P ϭ 0.037 versus control, t-test). In contrast, the mean neutrophil count of control patients was 3.37 Ϯ 0.52 ϫ10 3 per mm 3 at EF and decreased to 3.13 Ϯ 0.49ϫ10 3 per mm 3 2144 at LF (decrease of 0.24 Ϯ 0.97 ϫ10 3 per mm 3 , no significant change). Other leukocytic lineages were unaffected. Furthermore, neither patients nor controls had significant changes of haemoglobin/haematocrit or platelet counts.
Menotrophin treatment was associated with a significant increase in G-CSF concentrations (Figure 1) . In treated patients, the mean G-CSF concentration rose from 13.7 Ϯ 3.06 pg/ml at EF to 36.9 Ϯ 7.12 pg/ml at LF: this represents a mean 5.95 Ϯ 2.88-fold increase as the mean of the individual increases (P ϭ 0.028 versus control, Mann-Whitney rank sum test). In control subjects, the mean G-CSF concentration was essentially unchanged between EF (16.5 Ϯ 3.90 pg/ml) and LF (16.4 Ϯ 2.87 pg/ml). G-CSF concentrations remained elevated at the mid-luteal phase (Table I ). In treated patients there was a significant correlation between WBC count and serum G-CSF concentration at the LF phase (r ϭ 0.64, P ϭ 0.037, Spearman rank order correlation).
Estimates of mean M-CSF are given in Table I and showed no significant increase within individuals from baseline values. Estimates of IL-6 concentrations included measurements which were below the sensitivity of the assay in patients and subjects. Mean baseline concentrations for both groups were Ͻ0.5 pg/ ml and, at LF, mean concentrations for patients were 0.7 pg/ ml while controls remained at Ͻ0.5 pg/ml; these changes were not significant.
Discussion
The study demonstrates that women who undergo ovarian stimulation with urinary exogenous gonadotrophins, specifically, menotrophins, experience a significant increase in WBC counts and serum concentrations of G-CSF. The rise in G-CSF is parallel to the stimulation, and, contrary to the rise in WBC counts, could not be shown to extend into the mid-luteal phase. Other cytokines which were measured, M-CSF and interleukin-6, appeared to increase in stimulated patients, but this increase was not statistically significant.
While in the preliminary observation patients also received another medication (leuprolide acetate) (Kemmann and Fisch, 1995) , the current study excluded the use of this agent. Further, the current study was performed prospectively and included a control group which underwent daily sham injections. The control group of regular cycling women also had WBC determination at the beginning and towards the end of the follicular phase and demonstrated no significant WBC alteration during that part of the normal cycle. The current study further extended the observation that WBC counts not only rise in treated women towards the end of the stimulation phase, but rise further into the mid-luteal phase. WBC counts, indeed, were highest when measured in the mid-luteal phase. While our study did not obtain a control value for the mid-luteal phase, we are unaware of any evidence that normally cycling women develop leukocytosis during the mid-luteal phase.
The finding of a leukocytosis in response to the stimulation process of the ovary has been observed in those patients who develop OHSS (Loret de Mola et al., 1996a) . In contrast, the current study suggests that leukocytosis is a common response to urinary menotrophins and not a specific feature of OHSS. However, it is likely that leukocytosis is more pronounced in OHSS. In a retrospective study, Loret de Mola et al. (1996b) indicated that IL-6 concentrations are higher in women undergoing ovarian stimulation, with or without development of the hyperstimulation syndrome, than in unstimulated controls. Similarly, Abramov et al. (1996) reported that cytokine concentrations were elevated upon hospital admission for OHSS, and decreased with clinical improvement. While in our study, IL-6 concentrations increased somewhat, this rise was not found to be significant, and is consistent with the less stimulated state of our patients when compared to patients in the two aforementioned studies.
Cytokines are increasingly recognized as potentially important local regulators of ovarian function (Erickson and Danforth, 1995) . There is evidence that G-CSF is produced by the human ovary (Zhao et al., 1995) . Haematopoietic cytokines may be produced by various ovarian organs such as follicles, leukocytes and epithelium (Ziltener et al., 1993) . In addition, Giacomini et al. (1995) recently demonstrated that human endometrium can also produce G-CSF. Thus, it can be speculated that gonadotrophin stimulation of the ovary may generate an increased production of G-CSF directly by ovarian stimulation and/or indirectly via ovarian oestrogen production with stimulation of the endometrium. In either or both scenarios, WBC count would be increased. Our observations are therefore compatible with a view that leukocytosis is a common response to menotrophin therapy which is, at least in part, mediated by an increase in G-CSF and involves ovarian stimulation. It is of some interest also to point out that G-CSF concentrations have been reported to increase in normal pregnancy (Umesaki et al., 1995) . In addition, leukocytosis with relative lymphopenia is present as a physiological event during pregnancy (Johnstone et al., 1994) .
The current study utilized urinary follicle-stimulating hormone (FSH) as the agent to stimulate the ovaries. Urinary gonadotrophins contain a large number of unidentified proteins (Guidice et al., 1995) . Thus, it is possible that the urinary preparation of FSH contains components which lead to leukocytosis and to stimulation of G-CSF unrelated to FSH-based ovarian stimulation. Studies with recombinant FSH should clarify this situation. In either case, the ability of urinary FSH, be it as FSH or through an as yet unidentified agent, to stimulate granulocytosis is of pharmacological interest.
An important clinical implication of the study is the observation that women who receive exogenous gonadotrophins have elevated WBC counts as part of their physiological response. Thus, the presence of a rise in WBC count, an important diagnostic tool in many clinical situations, may be mistaken as a sign of a critical disease process by the unwary physician.
In summary, our data indicate that women who undergo ovarian stimulation with urinary gonadotrophins demonstrate a significant and progressive rise in their WBC numbers due to granulocytosis. While it is conceivable that this is caused through ovarian stimulation, and mediated, at least in part, by G-CSF, it will be of interest to determine whether a similar response is observed when recombinant FSH is used.
